Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials

References

• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 avr 8;362(14):1273‑81.
   Web of Science ®Google Scholar
• Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010 août 10;103(4):469‑74.
   PubMed Web of Science ®Google Scholar
• Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014 févr 1;25(2):391‑8.
   Web of Science ®Google Scholar
• Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021 mai;22(5):690‑701.
   Web of Science ®Google Scholar
• Verlingue L, Malka D, Allorant A, et al. Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. Eur J Cancer. 2017;87:122‑30.
   PubMed Web of Science ®Google Scholar
• Jusakul A, Cutcutache I, Yong CH, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017 oct;7(10):1116‑35.
   Web of Science ®Google Scholar
• Chae H, Kim D, Yoo C, et al. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker. Eur J Cancer. 2019;120:31‑9.
   PubMed Web of Science ®Google Scholar
• Tella SH, Kommalapati A, Borad MJ, et al. Second-line therapies in advanced biliary tract cancers. Lancet Oncol. 2020 janv;21(1):e29‑41.
   PubMed Web of Science ®Google Scholar
• Javle MM, Murugesan K, Shroff RT, et al. University of Texas MD Anderson Cancer Center H, Foundation Medicine I, The University of Texas MD Anderson Cancer Center H, Mayo Clinic Cancer Center S, Assiut University Hospital F of M, et al. Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH). [cité 13 févr 2021]; Disponible sur:https://meetinglibrary.asco.org/record/173260/abstract
   Google Scholar
• Lamarca A, Barriuso J, McNamara MG, et al. Molecular targeted therapies: ready for « prime time » in biliary tract cancer. J Hepatol. 2020 juill;73(1):170‑85.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Barriuso J, McNamara MG, et al. Biliary tract cancer: State of the art and potential role of DNA damage repair. Cancer Treat Rev. 2018 nov;70:168‑77.
   PubMed Web of Science ®Google Scholar
• Luchini C, Nottegar A. The roles of chromatin remodeling genes in pancreatic-biliary malignancies. Crit Rev Oncog. 2017;22(5‑6):471‑9.
   PubMedGoogle Scholar
• Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013 déc;45(12):1470‑3.
   Web of Science ®Google Scholar
• Salati M, Caputo F, Baldessari C, et al. IDH Signalling Pathway in Cholangiocarcinoma: from Biological Rationale to Therapeutic Targeting. Cancers (Basel). 2020 nov 9;12:11.
   Web of Science ®Google Scholar
• Valle JW, Lamarca A, Goyal L, et al. New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discov. 2017 sept;7(9):943‑62.
   PubMed Web of Science ®Google Scholar
• Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer. 2016 déc 15;122(24):3838‑47.
   Web of Science ®Google Scholar
• Kipp BR, Voss JS, Kerr SE, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012 oct;43(10):1552‑8.
   Web of Science ®Google Scholar
• Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 juin;21(6):796‑807.
   Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015 sept;47(9):1003‑10.
   Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020 mai;21(5):671‑84.
   Web of Science ®Google Scholar
• Javle M, Lowery M, Shroff RT, et al. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018 janv 20;36(3):276‑82.
   PubMed Web of Science ®Google Scholar
• Javle M, Kelley R, Roychowdhury S et al. Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. [cité 13 févr 2021]; Disponible sur: https://meetinglibrary.asco.org/record/194241/abstract
   Google Scholar
• Goyal L, Meric-Bernstam F, Hollebecque A, et al. FOENIX-CCA2: a phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements. JCO. 2020 mai 20;38(15_suppl):108‑108.
   Google Scholar
• Rizzo A, Ricci AD, Brandi G. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Expert Opin Investig Drugs. 2021 avr;30(4):317‑24.
   Web of Science ®Google Scholar
• Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019 janv;120(2):165‑71.
   PubMed Web of Science ®Google Scholar
• Zou S, Li J, Zhou H, et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun. 2014 déc 15;5(1):5696.
   PubMed Web of Science ®Google Scholar
• Simbolo M, Fassan M, Ruzzenente A, et al. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget. 2014 mai 15;5(9):2839‑52.
   PubMedGoogle Scholar
• Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020 sept;21(9):1234‑43.
   Web of Science ®Google Scholar
• Nam A-R, Kim J-W, Cha Y, et al. Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget. 2016 sept 6;7(36):58007‑21.
   Google Scholar
• Meric-Bernstam F, Hanna DL, El-Khoueiry AB, et al. Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): results from a phase I study. Am Soc Clin Oncol. 2021;39(3_suppl):299-299. DOI: https://doi.org/10.1200/JCO.2021.39.3_suppl.299.
   Google Scholar
• Jacobi O, Ross JS, Goshen-Lago T, et al. ERBB2 Pathway in Biliary Tract Carcinoma: clinical Implications of a Targetable Pathway. Oncol Res Treat. 2021;44(1‑2):20‑7.
   PubMed Web of Science ®Google Scholar
• Harding J, Cleary J, Shapiro G, et al. Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: results from the phase II SUMMIT ‘basket’ trial. [cité 14 févr 2021]; Disponible sur: https://meetinglibrary.asco.org/record/194339/abstract
   Google Scholar
• Bahleda R, Italiano A, Hierro C, et al. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. Clin Cancer Res. 2019 août 15;25(16):4888‑97.
   Web of Science ®Google Scholar
• Bahleda R, Meric-Bernstam F, Goyal L, et al. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. Ann Oncol. 2020 oct;31(10):1405‑12.
   PubMed Web of Science ®Google Scholar
• Voss MH, Hierro C, Heist RS, et al. A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Clin Cancer Res. 2019 mai 1;25(9):2699‑707.
   Web of Science ®Google Scholar
• Ross JS, Wang K, Gay L, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014 mars;19(3):235‑42.
   Web of Science ®Google Scholar
• Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018 déc;15(12):731‑47.
   PubMed Web of Science ®Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018 févr 22;378(8):731‑9.
   PubMed Web of Science ®Google Scholar
• Golan T, Raitses‐Gurevich M, Kelley RK, et al. Overall Survival and Clinical Characteristics of BRCA‐Associated Cholangiocarcinoma: a Multicenter Retrospective Study. Oncologist. 2017 juill;22(7):804‑10.
   PubMed Web of Science ®Google Scholar
• Spizzo G, Puccini A, Xiu J et al. Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI). [cité 14 févr 2021]; Disponible sur:https://meetinglibrary.asco.org/record/173298/abstract
   Google Scholar
• Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274‑84.
   PubMed Web of Science ®Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 01; 375(22): 2154‑64.
   PubMed Web of Science ®Google Scholar
• Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018 27; 379(26): 2495‑505.
   Web of Science ®Google Scholar
• González-Martín A, Pothuri B, Vergote I, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019 19; 381(25): 2391‑402.
   Web of Science ®Google Scholar
• Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018 23; 379(8): 753‑63.
   PubMed Web of Science ®Google Scholar
• Robson M, Im S-A, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017 juin 4;0:null.
   Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017 juill 28;357(6349):409‑13.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017 juill 28;357(6349):409‑13.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: results From the Phase II KEYNOTE-158 Study. J clin oncol. 2020 janv 1;38(1):1‑10.
   Web of Science ®Google Scholar
• Qin S, Chen Z, Liu Y et al. A phase II study of anti–PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer. [cité 14 févr 2021]; Disponible sur: https://meetinglibrary.asco.org/record/173222/abstract
   Google Scholar
• Floudas C, Xie C, Brar G et al. Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC). [cité 14 févr 2021]; Disponible sur:https://meetinglibrary.asco.org/record/169352/abstract
   Google Scholar
• Chen X, Wu X, Wu H et al. SHR-1210 combined with GEMOX as first-line treatment in patients with advanced biliary tract cancer. [cité 14 févr 2021]; Disponible sur: https://meetinglibrary.asco.org/record/182815/abstract
   Google Scholar
• 3D Medicines (Sichuan) Co., Ltd. Gemcitabine and Oxaliplatin With or Without KN035 for Biliary Tract Cancer: a Randomised, Open-label, Parallel-group, Multicenter Phase III Study [Internet]. clinicaltrials.gov; 2019 déc [cité 2021 févr 11]. Report No.: NCT03478488. Disponible sur: https://clinicaltrials.gov/ct2/show/NCT03478488
   Google Scholar
• EMD Serono Research & Development Institute, Inc. A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer [Internet]. clinicaltrials.gov; 2021 janv [cité 2021 févr 11]. Report No.: NCT04066491. Disponible sur: https://clinicaltrials.gov/ct2/show/NCT04066491
   Google Scholar
• Jang S, Chun S-M, Hong S-M, et al. High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases. Mod Pathol. 2014 mai;27(5):731‑9.
   Web of Science ®Google Scholar
• Leone F, Cavalloni G, Pignochino Y, et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res. 2006 mars 15;12(6):1680‑5.
   PubMed Web of Science ®Google Scholar
• Walter D, Hartmann S, Waidmann O. Update on cholangiocarcinoma: potential impact of genomic studies on clinical management. Z Gastroenterol. 2017 juin;55(6):575‑81.
   Web of Science ®Google Scholar
• Valle JW, Wasan H, Lopes A, et al. Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncol. 2015 août;16(8):967‑78.
   PubMed Web of Science ®Google Scholar
• Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014 juill;15(8):819‑28.
   PubMed Web of Science ®Google Scholar
• Lee J, Park SH, Chang H-M, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2012 févr;13(2):181‑8.
   Web of Science ®Google Scholar
• Sohal DPS, Mykulowycz K, Uehara T, et al. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. Ann Oncol. 2013 déc;24(12):3061‑5.
   PubMed Web of Science ®Google Scholar
• Miranda Furtado CL, Dos Santos Luciano MC, Silva SRD, et al. Epidrugs: targeting epigenetic marks in cancer treatment. Epigenetics. 2019 juill 13;14(12):1164‑76.
   PubMed Web of Science ®Google Scholar
• Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020 sept;17(9):557‑88.
   PubMed Web of Science ®Google Scholar
• Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016 mai;13(5):261‑80.
   PubMed Web of Science ®Google Scholar
• Kuznetsov JN, Aguero TH, Owens DA, et al. BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers. Sci Adv. 2019 sept 1;5(9):eaax1738.
   PubMed Web of Science ®Google Scholar
• Huang K, Sun R, Chen J, et al. A novel EZH2 inhibitor induces synthetic lethality and apoptosis in PBRM1-deficient cancer cells. null. 2020 avr 2;19(7):758‑71.
   Google Scholar
• Bitler BG, Aird KM, Garipov A, et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med. 2015;21(3):231‑8.
   PubMed Web of Science ®Google Scholar
• Chabanon RM, Morel D, Colmet-Daage L, et al. Abstract 1058: targeting chromatin remodeling-associated genetic vulnerabilities in cancer: PBRM1 defects are synthetic lethal with PARP and ATR inhibitors. Cancer Res. 2020 août 15;80(16Supplement):1058.
   Google Scholar
• Kasi PM. Favorable Outcomes in FGFR Fusion-Positive Cholangiocarcinomas and Evolution on Treatment Noted on Circulating Tumor DNA Liquid Biopsies. Case Rep Oncol. 2020 août;13(2):941‑7.
   Web of Science ®Google Scholar
• Lapitz A, Arbelaiz A, O’Rourke CJ, et al. Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: novel Liquid Biopsy Biomarkers for Disease Diagnosis. Cells. 2020 mars 14;9:3.
   Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Tavolari S, et al. Circulating Tumor DNA in Biliary Tract Cancer: current Evidence and Future Perspectives. Cancer Genomics Proteomics. 2020 oct;17(5):441‑52.
   PubMed Web of Science ®Google Scholar
• Narita Y, Matsushima Y, Shiroiwa T, et al. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer. Lung Cancer. 2015 oct;90(1):71‑7.
   PubMed Web of Science ®Google Scholar
• Tan AC, Lai GGY, Tan GS, et al. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: incremental yield of actionable alterations and cost-effectiveness analysis. Lung Cancer. 2020;139:207‑15.
   PubMed Web of Science ®Google Scholar
• Zhu A, Macarulla T, Javle M et al. Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation. [cité 14 févr 2021]; Disponible sur:https://meetinglibrary.asco.org/record/194236/abstract
   Google Scholar